NCT06496048 2024-12-12
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
Luye Pharma Group Ltd.
Phase 3 Recruiting
Luye Pharma Group Ltd.
Beijing Chest Hospital
SWOG Cancer Research Network
Japan Clinical Oncology Group
Pfizer